Ambrx to Participate in Panel Discussion at the H.C. Wainwright 23rd Annual Global Investment Conference
09 Setembro 2021 - 5:30PM
Business Wire
- Discussion to focus on engineered cytokines
and their role in immune-oncology -
Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company
using an expanded genetic code technology platform to create
Engineered Precision Biologics, today announced that Feng Tian,
Ph.D., President and Chief Executive Officer of Ambrx, will
participate in a virtual panel discussion at the H.C. Wainwright
23rd Annual Global Investment Conference, taking place September
13-15, 2021. The discussion will be led by Michael King, Managing
Director and Senior Biotechnology Analyst at H.C. Wainwright.
Discussion Topic: Engineered Cytokines: The Next Big Wave
in Immuno-Oncology. Date and Time: Tuesday, September 14,
2021, at 1:30 pm EDT, 10:30 am PDT.
Individuals interested in listening to the panel discussion may
do so using the webcast link under “Latest Events” in the Investors
section of the company's website at: www.ambrx.com.
About Ambrx
Ambrx is a clinical stage biopharmaceutical company using an
expanded genetic code technology platform to discover and develop
Engineered Precision Biologics. These include next generation
antibody drug conjugates (ADCs), bispecifics, targeted
immuno-oncology therapies, novel cytokines to modulate the immune
system, and long-acting therapeutic peptides for metabolic and
cardiovascular disease. Ambrx is advancing a robust portfolio of
clinical and preclinical programs designed to optimize efficacy,
safety and ease of use, in multiple therapeutic areas, including
its lead product candidate ARX788. In addition, the company has
clinical collaborations, with multiple partners, for drug
candidates generated using Ambrx technology. For additional
information, please visit www.ambrx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210909006086/en/
INVESTORS Laurence Watts Managing Director Gilmartin Group, LLC.
619-916-7620 ir@ambrx.com
MEDIA Ian Stone Managing Director Canale Communications (619)
849-5388 media@ambrx.com
Ambrx Biopharma (NYSE:AMAM)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Ambrx Biopharma (NYSE:AMAM)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
